How I treat poisoning with vitamin K antagonists

Blood

Volumn 125, Issue 3, 2015, Pages 438-442

  Schulman, Sol ^a   Furie, Bruce ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN III; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; FRESH FROZEN PLASMA; HEMOGLOBIN; PROTHROMBIN; VITAMIN K DEPENDENT CARBOXYLASE; VITAMIN K GROUP; ANTICOAGULANT AGENT; RODENTICIDE;

ADULT; AGED; ANKLE; ARTICLE; BACK; BLEEDING; BLOOD CLOTTING DISORDER; CASE REPORT; CLINICAL EXAMINATION; DIFFERENTIAL DIAGNOSIS; DIZZINESS; ECCHYMOSIS; ENZYME DEFICIENCY; EPISTAXIS; FACE; FEMALE; HEMATOCRIT; HEMATOMA; HEMATURIA; HEMOGLOBIN BLOOD LEVEL; HEMOSTASIS; HUMAN; INGESTION; INTERNATIONAL NORMALIZED RATIO; INTOXICATION; MALABSORPTION; MALE; MIDDLE AGED; PAIN; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTHROMBIN TIME; THROMBIN TIME; THROMBOCYTE COUNT; VITAMIN INTAKE; VITAMIN K DEFICIENCY; WEAKNESS; WRIST; ANTAGONISTS AND INHIBITORS; BLOOD; BLOOD COAGULATION DISORDERS; COMPLICATION; HEMORRHAGE; PROGNOSIS;

AGED; ANTICOAGULANTS; BLOOD COAGULATION DISORDERS; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RODENTICIDES; VITAMIN K;

EID: 84921367690     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-08-597781     Document Type: Article

References (52)

1. Stenflo J, Fernlund P, Egan W, Roepstorff P. Vitamin K dependent modifications of glutamic acid residues in prothrombin. Proc Natl Acad Sci USA. 1974;71(7):2730-2733.
2. Nelsestuen GL, Zytkovicz TH, Howard JB. The mode of action of vitamin K. Identification of gamma-carboxyglutamic acid as a component of prothrombin. J Biol Chem. 1974;249(19): 6347-6350.
3. Furie B, Bouchard BA, Furie BC. Vitamin K-dependent biosynthesis of gammacarboxyglutamic acid. Blood. 1999;93(6): 1798-1808.
4. Soriano-Garcia M, Padmanabhan K, de Vos AM, Tulinsky A. The Ca2+ ion and membrane binding structure of the Gla domain of Ca-prothrombin fragment 1. Biochemistry. 1992;31(9):2554-2566.
5. Wood GM, Suttie JW. Vitamin K-dependent carboxylase. Stoichiometry of vitamin K epoxide formation, gamma-carboxyglutamyl formation, and gamma-glutamyl-3H cleavage. J Biol Chem. 1988;263(7):3234-3239.
6. Li T, Chang CY, Jin DY, Lin PJ, Khvorova A, Stafford DW. Identification of the gene for vitamin K epoxide reductase. Nature. 2004;427(6974): 541-544.
7. Rost S, Fregin A, Ivaskevicius V, et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature. 2004;427(6974):537-541.
8. Silverman RB, Nandi DL. Reduced thioredoxin: a possible physiological cofactor for vitamin K epoxide reductase. Further support for an active site disulfide. Biochem Biophys Res Commun. 1988;155(3):1248-1254.
9. Wajih N, Hutson SM, Wallin R. Disulfide-dependent protein folding is linked to operation of the vitamin K cycle in the endoplasmic reticulum. A protein disulfide isomerase-VKORC1 redox enzyme complex appears to be responsible for vitamin K1 2,3-epoxide reduction. J Biol Chem. 2007;282(4):2626-2635.
10. Li W, Schulman S, Dutton RJ, Boyd D, Beckwith J, Rapoport TA. Structure of a bacterial homologue of vitamin K epoxide reductase. Nature. 2010;463(7280):507-512.
11. Schulman S, Wang B, Li W, Rapoport TA. Vitamin K epoxide reductase prefers ER membraneanchored thioredoxin-like redox partners. Proc Natl Acad Sci USA. 2010;107(34):15027-15032.
12. Zipursky A. Prevention of vitamin K deficiency bleeding in newborns. Br J Haematol. 1999; 104(3):430-437.
13. Blanchard RA, Furie BC, Jorgensen M, Kruger SF, Furie B. Acquired vitamin K-dependent carboxylation deficiency in liver disease. N Engl J Med. 1981;305(5):242-248.
14. Liebman HA, Furie BC, Furie B. Hepatic vitamin K-dependent carboxylation of blood-clotting proteins. Hepatology. 1982;2(4):488-494.
15. Suttie JW, Mummah-Schendel LL, Shah DV, Lyle BJ, Greger JL. Vitamin K deficiency from dietary vitamin K restriction in humans. Am J Clin Nutr. 1988;47(3):475-480.
16. Ferland G, Sadowski JA, O'Brien ME. Dietary induced subclinical vitamin K deficiency in normal human subjects. J Clin Invest. 1993;91(4): 1761-1768.
17. Conly J, Stein K. Reduction of vitamin K2 concentrations in human liver associated with the use of broad spectrum antimicrobials. Clin Invest Med. 1994;17(6):531-539.
18. Conly JM, Stein KE. The absorption and bioactivity of bacterially synthesized menaquinones. Clin Invest Med. 1993;16(1): 45-57.
19. Suttie JW. The importance of menaquinones in human nutrition. Annu Rev Nutr. 1995;15: 399-417.
20. Deitcher SR. Interpretation of the international normalised ratio in patients with liver disease. Lancet. 2002;359(9300):47-48.
21. Wu SM, Cheung WF, Frazier D, Stafford DW. Cloning and expression of the cDNA for human gamma-glutamyl carboxylase. Science. 1991; 254(5038):1634-1636.
22. Libby EN, Garcia DA. A survey of oral vitamin K use by anticoagulation clinics. Arch Intern Med. 2002;162(16):1893-1896.
23. White HD, Gruber M, Feyzi J, et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med. 2007;167(3):239-245.
24. O'Reilly RA, Aggeler PM. Covert anticoagulant ingestion: study of 25 patients and review of world literature. Medicine (Baltimore). 1976;55(5): 389-399.
25. Mowry JB, Spyker DA, Cantilena LR Jr, Bailey JE, Ford M. 2012 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 30th Annual Report. Clin Toxicol (Phila). 2013;51(10): 949-1229.
26. Hadler MR, Shadbolt RS. Novel 4-hydroxycoumarin anticoagulants active against resistant rats. Nature. 1975;253(5489):275-277.
27. Bachmann KA, Sullivan TJ. Dispositional and pharmacodynamic characteristics of brodifacoum in warfarin-sensitive rats. Pharmacology. 1983; 27(5):281-288.
28. Schulman S, Kearon C; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692-694.
29. Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e44S-88S.
30. Rosovsky RP, Crowther MA. What is the evidence for the off-label use of recombinant factor VIIa (rFVIIa) in the acute reversal of warfarin? ASH evidence-based review 2008. Hematology (Am Soc Hematol Educ Program). 2008;36-38.
31. Goodnough LT, Shander A. How I treat warfarin-associated coagulopathy in patients with intracerebral hemorrhage. Blood. 2011;117(23): 6091-6099.
32. Ageno W, Garcia D, Aguilar MI, et al. Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, part 2: treatment. Am J Hematol. 2009;84(9):584-588.
33. Lubetsky A, Yonath H, Olchovsky D, Loebstein R, Halkin H, Ezra D. Comparison of oral vs intravenous phytonadione (vitamin K1) in patients with excessive anticoagulation: a prospective randomized controlled study. Arch Intern Med. 2003;163(20):2469-2473.
34. Fiore LD, Scola MA, Cantillon CE, Brophy MT. Anaphylactoid reactions to vitamin K. J Thromb Thrombolysis. 2001;11(2):175-183.
35. Weitzel JN, Sadowski JA, Furie BC, et al. Surreptitious ingestion of a long-acting vitamin K antagonist/rodenticide, brodifacoum: clinical and metabolic studies of three cases. Blood. 1990;76(12):2555-2559.
36. Spahr JE, Maul JS, Rodgers GM. Superwarfarin poisoning: a report of two cases and review of the literature. Am J Hematol. 2007;82(7):656-660.
37. Breckenridge AM, Cholerton S, Hart JA, Park BK, Scott AK. A study of the relationship between the pharmacokinetics and the pharmacodynamics of the 4-hydroxycoumarin anticoagulants warfarin, difenacoum and brodifacoum in the rabbit. Br J Pharmacol. 1985;84(1):81-91.
38. Palmer RB, Alakija P, de Baca JE, Nolte KB. Fatal brodifacoum rodenticide poisoning: autopsy and toxicologic findings. J Forensic Sci. 1999;44(4): 851-855.
39. Hollinger BR, Pastoor TP. Case management and plasma half-life in a case of brodifacoum poisoning. Arch Intern Med. 1993;153(16): 1925-1928.
40. Kuwada M, Katayama K. An improved method for the determination of gamma-carboxyglutamic acid in proteins, bone, and urine. Anal Biochem. 1983;131(1):173-179.
41. Shearer MJ, Fu X, Booth SL. Vitamin K nutrition, metabolism, and requirements: current concepts and future research. Adv Nutr. 2012;3(2):182-195.
42. Park BK, Scott AK, Wilson AC, Haynes BP, Breckenridge AM. Plasma disposition of vitamin K1 in relation to anticoagulant poisoning. Br J Clin Pharmacol. 1984;18(5):655-662.
43. Bjornsson TD, Blaschke TF. Vitamin K1 disposition and therapy of warfarin overdose. Lancet. 1978;2(8094):846-847.
44. Suttie JW. Mechanism of action of vitamin K: synthesis of gamma-carboxyglutamic acid. CRC Crit Rev Biochem. 1980;8(2):191-223.
45. Wallin R. Vitamin K antagonism of coumarin anticoagulation. A dehydrogenase pathway in rat liver is responsible for the antagonistic effect. Biochem J. 1986;236(3):685-693.
46. Wallin R, Gebhardt O, Prydz H. NAD(P)H dehydrogenase and its role in the vitamin K (2-methyl-3-phytyl-1,4-naphthaquinone)-dependent carboxylation reaction. Biochem J. 1978;169(1):95-101.
47. Wallin R, Martin LF. Vitamin K-dependent carboxylation and vitamin K metabolism in liver. Effects of warfarin. J Clin Invest. 1985;76(5): 1879-1884.
48. Wallin R, Hutson S. Vitamin K-dependent carboxylation. Evidence that at least two microsomal dehydrogenases reduce vitamin K1 to support carboxylation. J Biol Chem. 1982; 257(4):1583-1586.
49. Asher G, Dym O, Tsvetkov P, Adler J, Shaul Y. The crystal structure of NAD(P)H quinone oxidoreductase 1 in complex with its potent inhibitor dicoumarol. Biochemistry. 2006;45(20): 6372-6378.
50. Wallin R, Martin LF. Warfarin poisoning and vitamin K antagonism in rat and human liver. Design of a system in vitro that mimics the situation in vivo. Biochem J. 1987;241(2): 389-396.
51. Fasco MJ, Principe LM. R- and S-warfarin inhibition of vitamin K and vitamin K 2,3-epoxide reductase activities in the rat. J Biol Chem. 1982; 257(9):4894-4901.
52. Ingram BO, Turbyfill JL, Bledsoe PJ, Jaiswal AK, Stafford DW. Assessment of the contribution of NAD(P)H-dependent quinone oxidoreductase 1 (NQO1) to the reduction of vitamin K in wild-type and NQO1-deficient mice. Biochem J. 2013; 456(1):47-54.